Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 21, 2021 08:00 ET | Source: TFF Pharmaceuticals, Inc.

TFF Pharmaceuticals Announces Final Data from Phase 1b Study of Inhaled Voriconazole Powder in Asthma Patients

Final Safety and Pharmacokinetic Data Continue to Support Progression to Phase 2 in the Near Term for Treatment of Invasive Pulmonary Aspergillosis (IPA), Including Patients with Mild to Moderate...
December 06, 2021 08:00 ET | Source: TFF Pharmaceuticals, Inc.

TFF Pharmaceuticals Hosting Science Day on December 13, 2021

AUSTIN, Texas, Dec. 06, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...
November 15, 2021 16:01 ET | Source: TFF Pharmaceuticals, Inc.

TFF Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update

Positive Updates Announced for Inhaled Voriconazole and Tacrolimus Programs;Both Programs Advancing into Phase 2 Testing Continued Progress with Partnered Antiviral Programs for AUG-3387 and...
November 08, 2021 08:03 ET | Source: TFF Pharmaceuticals, Inc.

TFF Pharmaceuticals Announces Completion of Dosing of Phase 1b Study for Voriconazole Inhalation Powder in Mild to Moderate Asthma Patients

Initial data from Phase 1b showed Voriconazole Inhalation Powder is Well Tolerated in Asthma Patients Data Supports Progress to Phase 2 and Inclusion of Patients with Asthma AUSTIN, Texas, Nov. ...
November 08, 2021 08:00 ET | Source: TFF Pharmaceuticals, Inc.

TFF Pharmaceuticals to Participate in the 12th Annual Jefferies London Healthcare Conference 2021

AUSTIN, Texas, Nov. 08, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...
November 05, 2021 16:05 ET | Source: TFF Pharmaceuticals, Inc.

TFF Pharmaceuticals to Hold Third Quarter 2021 Financial and Business Results Conference Call on November 15, 2021

AUSTIN, Texas, Nov. 05, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...
October 28, 2021 09:16 ET | Source: TFF Pharmaceuticals, Inc.

TFF Pharmaceuticals Receives Approval from Health Canada to Enter Human Clinical Trials for Inhaled Formulation of Niclosamide to Treat COVID-19

First Patient in Phase 1 Trial to be Dosed in November with Enrollment Completion Anticipated by Early Q1 2022 Preclinical Studies of Inhaled Dry Powder Formulation of Niclosamide Showed a...
October 14, 2021 08:30 ET | Source: TFF Pharmaceuticals, Inc.

TFF Pharmaceuticals and Augmenta Bioworks Publish Positive In Vivo Data Showing Dry Powder Formulation of COVID-19 Antibody, AUG-3387, Neutralizes SARS-CoV-2 Infection and Reduces Viral Load

Results published in bioRxiv Show That Delivery of Dry Powder AUG-3387 Following Viral Inoculation Led to Dose-Dependent Reduction in Lung Viral Load in Hamsters Dry Powder Formulations Show...
September 23, 2021 08:00 ET | Source: TFF Pharmaceuticals, Inc.

TFF Pharmaceuticals Announces Promising Topline Results from Phase 1 Clinical Trial of Inhaled Tacrolimus Powder and Progression Toward Phase 2 in Lung Transplantation

AUSTIN, Texas, Sept. 23, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...
September 08, 2021 16:05 ET | Source: TFF Pharmaceuticals, Inc.

TFF Pharmaceuticals to Present at 23rd H.C. Wainwright Annual Global Investment Conference

AUSTIN, Texas, Sept. 08, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...